XLH Patient Meeting Showcases Value Of Post-Approval Feedback To US FDA
X-Linked Hypophosphatemia patient feedback meeting follows recent approval of Ultragenyx’ Crysvita. Like an SMA meeting in 2017, it showed how post-approval meetings can help sustain momentum in a new class.
You may also be interested in...
Trump Administration’s successful campaign to pass “Right to Try” legislation may be emboldening advocates to push for other policies that will loosen FDA regulatory requirements on rare disease drug development.
The latest drug development news and highlights from our US FDA Performance Tracker.
US agency's top neurology review officials received warm reception during Patient Focused Drug Development meeting for Spinal Muscular Atrophy. They also delivered a strong message of continued engagement beyond the first drug approval.